NCT01137643 Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
| NCT ID | NCT01137643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UNC Lineberger Comprehensive Cancer Center |
| Condition | Chronic Myeloproliferative Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 15,000 participants |
| Start Date | 2009-07 |
| Primary Completion | 2040-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 15,000 participants in total. It began in 2009-07 with a primary completion date of 2040-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Eligibility Criteria
DISEASE CHARACTERISTICS: * Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following: * Acute myeloid leukemia * Acute lymphoblastic leukemia * Chronic myelogenous leukemia * Chronic lymphoid leukemia * Non-Hodgkin lymphoma * Hodgkin lymphoma * Myelodysplastic syndromes * Myeloproliferative disorders * Multiple myeloma * Waldenstrom macroglobulinemia * Aplastic anemia * Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage * Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Contact & Investigator
Paul Armistead, MD
PRINCIPAL INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT01137643 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Chronic Myeloproliferative Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01137643 currently recruiting?
Yes, NCT01137643 is actively recruiting participants. Contact the research team at paul_armistead@med.unc.edu for enrollment information.
Where is the NCT01137643 trial being conducted?
This trial is being conducted at Chapel Hill, United States.
Who is sponsoring the NCT01137643 clinical trial?
NCT01137643 is sponsored by UNC Lineberger Comprehensive Cancer Center. The principal investigator is Paul Armistead, MD at UNC Lineberger Comprehensive Cancer Center. The trial plans to enroll 15,000 participants.